31 – 40 of 392
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Effect of single-dose DPP-4 inhibitor sitagliptin on β-cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drug-naïve, well-controlled type 2 diabetes subjects
(
- Contribution to journal › Article
-
Mark
Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes : A randomized, placebo-controlled study
(
- Contribution to journal › Article
-
Mark
Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
(
- Contribution to journal › Article
-
Mark
Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3)
(
- Contribution to journal › Article
-
Mark
Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients
(
- Contribution to journal › Article
- 2017
-
Mark
Glucagon increases insulin levels by stimulating insulin secretion without effect on insulin clearance in mice
(
- Contribution to journal › Article
-
Mark
Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes : A randomized, open-label, 2-arm parallel comparative, exploratory trial
(
- Contribution to journal › Article
-
Mark
Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus : Results over 52 weeks
(
- Contribution to journal › Article
-
Mark
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2) : a 56-week, double-blind, phase 3a, randomised trial
(
- Contribution to journal › Article
-
Mark
Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day : An analysis using continuous glucose monitoring
(
- Contribution to journal › Article